GT Medical Raised $100M on Evidence, Not the Clearance It Already Had

A medical device company can hold an FDA clearance for nearly a decade and still not own the thing investors actually pay for. GT Medical Technologies is the clean example. Its GammaTile implant has been cleared since 2018, expanded to newly diagnosed tumors in 2020, and selling the entire time. Yet the hundred million dollars did not arrive until last week, after a randomized trial put the device against the standard of care and won. The clearance was years old. What changed was the evidence, and the capital followed it.

What the money was actually buying

GT Medical closed an oversubscribed $100 million Series E on June 9, led by new investor Viking Global, per the company and MedTech Dive. GammaTile is a bioresorbable implant placed in the cavity at the moment of brain tumor surgery, so radiation begins immediately instead of weeks later in a separate course. It has been cleared and on the market for years. What moved the round was the ROADS data shared at this year’s ASCO meeting: a Phase 3 randomized trial in newly diagnosed brain metastases where the twelve month surgical bed recurrence rate was 1.3 percent with GammaTile against 15.4 percent for surgery followed by stereotactic radiation, the current standard of care. Chief executive Per Langoe called the financing validation of the device’s potential to become a standard of care itself.

Clearance and evidence are two different games

A clearance answers one question: may you sell this. Comparative evidence answers a different one: should anyone switch to it. I have argued for years that framing the indication is the regulatory strategy, because how you define a device determines how much evidence the FDA will demand to clear it. At Galen we framed our system as a surgeon access stabilizer rather than a remote manipulator, which kept the bar on engineering and usability instead of a full clinical outcomes trial. That is the right first move, because it gets you to market cheaply and fast. But the outcomes trial you deliberately skipped is the same one that later moves adoption, reimbursement, and growth capital. GT Medical sequenced it well: clear on the cheaper framing, get on the market, then fund the randomized comparison once there is revenue and a reason to run it.

There is also a reason the data is believable, and it comes down to workflow. GammaTile closes a gap. The patient is already in the operating room for the resection, and the radiation source goes in during that same procedure, so there is no three to four week wait between surgery and the start of radiation and no second appointment to book. A device that slots into the operation already happening carries a real adoption advantage over one that asks the surgeon and the patient to add a step.

The pattern reaches well past MedTech. A defense hardware startup can pass the qualification testing that lets it sell to a program office and still be waiting on the field data that proves it beats the incumbent it wants to displace. A diagnostics company can clear its assay and still need the head-to-head accuracy study before a lab will switch vendors. Permission to sell and proof that you are worth switching to are different milestones, funded at different times, and treating them as one thing is how a cleared product can sit flat for years.

Dave Saunders is the founder of Base Reality Group and a Fractional CPO for hard-tech founders. He was a founder and operator at Galen Robotics, where the surgical-robotics platform earned FDA De Novo authorization in 2023, and he managed a 35-patent portfolio licensed from Johns Hopkins. He wrote Founders Who Finish and publishes The Build. More about Dave →